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Abstract
Breast milk represents nature’s best mechanism to provide complete nourish-
ment and protection to the newborn. Human breast milk acts as a store house of an
array of bioactive factors, which includes antimicrobial proteins and antimicrobial
peptides that confer early protection while lowering the incidence of developing
various infections and exhibiting immune modulation property to activate the
immune cells to fight against the invading pathogens. Among the bioactive pep-
tides, endogenous peptides present in breast milk have opened a new window of
research on studying their unique mechanisms of action. This will help in incorpo-
rating these peptides in formula milk for meeting special needs where breastfeeding
is not possible. The present chapter aims to give a deep insight into the various
antimicrobial peptides and the newly reported endogenous peptides in human
breast milk with emphasis on their levels and activity in preterm milk as data
related to this is lacking and preterm newborns are highly vulnerable to acquire
infections. Further, the chapter focuses on highlighting the antibacterial mecha-
nisms adopted by the bioactive peptides for protection against the neonatal bacte-
rial pathogens with special emphasis on the infections caused by resistant bacterial
strains in hospital settings (neonatal wards) and their future implications.
Keywords: breast milk, neonatal infections, antimicrobial proteins, antimicrobial
peptides, preterm, necrotizing Enterocolitis
1. Introduction
Breastfeeding provides a nursing infant with a plethora of bioactive molecules
evolved to optimally develop the infants overall health. Traditionally breast milk
was considered to serve only as a source of nutrition but breast milk is actually a
perfect store house of an array of bioactive molecules essential for the overall
development and protection of the newborn. It is considered as the best functional
food for all instances, whether preterm or full term that is produced specifically by
each mother to satisfy her unique infant. World Health Organization (WHO)
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recommends exclusive breastfeeding until 6 months and continuation of
breastfeeding until 2 years as part of mixed diet [1, 2]. Past studies clearly indicate
that as compared to formula fed infants, breast fed infants present lower incidence
of microbial infections, better quality and composition of their gut flora, better
cognitive functions, reduced risk of allergy with a stronger immunity to fight
against infections in their future as well [3–6].
These properties and benefits of breastfeeding are due to the presence of mul-
titude of bioactive molecules in human breast milk that help to protect the new-
born from pathogenic microbes while strengthening infant’s immune system.
Among the major bioactive molecules are the milk proteins present. Colostrum has
high concentration of proteins, is low in fat and carbohydrates than mature milk
indicating that its primary purpose is to provide immediately as many bioactive
proteins and peptides to the newborn aimed for its protection against microbial
insult [7, 8].
These bioactive proteins serve various physiological functions which include
enhancement of nutrient absorption by specific binding proteins facilitating the
uptake of nutrients, assistant in digestion and growth stimulation. One of the major
role of bioactive proteins is their antimicrobial effect as these molecules have broad
spectrum antimicrobial activity in vitro against bacteria, viruses, and fungi, as well
as synergistic activity with conventional antibiotics [9–11].
Antimicrobial proteins are multifunctional defense molecules that are highly con-
centrated in early lactation and decrease with progressing lactation. Their composi-
tion in milk changes to serve to the growing and changing needs of infant. They
present a strong defense against the pathogens thus protecting the highly vulnerable
infant while its immune system is still being developed. Antimicrobial proteins
(AMPrs) and antimicrobial peptides (AMPs) exhibit their effect through many
different mechanism and unique ways. They are involved in (a) direct outright killing
the microbes, (b) neutralizing the bacteria and viruses and making them ineffective
or (c) indirectly by blocking the initial attachment/adherence of the bacteria to
mucosal surfaces. Besides this, these molecules also modulate the immune system by
activating immune cells against infectious agents and strengthening the innate system
against life-threatening infections and those targeting the mucosal lining (gastroin-
testinal infections, skin infections, respiratory tract infections) [12–14]. The combi-
nation of immunomodulation and antimicrobial factors help the child to avoid the
development of various childhood infections and inflammatory diseases. Another
major role played by breast milk proteins is the development of infant’s gut flora
exerted due to the prebiotic effect [10, 15]. Therefore, breast milk is a unique and
complex reservoir of multitude of proteins and peptides all of which work in a
synergistic manner to maximize the benefits in favor of the growing infant.
Another area of interest pertains to endogenous peptides present in human milk
and their unique role that still warrants further research. These peptides are derived
from proteins by specific proteases, many possess antibacterial action [16, 17].
Studying such endogenous peptides especially their role in preterm milk is of
paramount importance in developing functional foods to cater to the special need of
low birth weight infants (LBW) as well as preterm infants that stand at a higher
chance of developing infections than term infants.
The role of milk derived antimicrobial proteins and peptides against neonatal
pathogens and their clinical utility is definitely a complex topic and needs more
detailed investigation. The present chapter focuses on various bioactive proteins
and peptides involved, their mechanisms, spectrum of activity against range of
bacterial infections with special emphasis on preterm infants and role of these
molecules against resistant infections that are on rise in neonatal wards. Finally,
future implications pertaining to use of newer technologies to exploit various
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human milk derived proteins and novel peptides as therapeutic and preventive
intervention strategy has been highlighted.
2. The human milk proteome
Human breast milk is an ideal nutrition to the infants consisting of 87% water,
1% protein, 4% lipid and 7% carbohydrate along with various minerals and vitamins
[15]. These bio-components of breast milk have been shown to provide bioactivities
that are important for infant growth and development. The largest variety of
bioactivities, however, is provided by proteins in breast milk [18].
Breast milk contains a wide array of proteins which are present in the form of
enzymes/proteases, glycoproteins, and endogenous peptides. They provide unique
biological activities, ranging from antimicrobial effects to immunostimulatory
functions, facilitating the digestion and uptake of other nutrients in the milk such as
iron, calcium and vitamin B besides providing sufficient amounts of essential amino
acids to breast-fed infants [8]. The concentration and composition of human milk
proteome changes continuously in their composition and concentration throughout
gestational age and lactation stage. Over the last several years, an extensive analysis
of the protein composition of term and preterm breast milk has been done [19–21].
Results indicate both quantitative as well as qualitative modifications through lac-
tation in both term and preterm breast milk. Breast milk obtained from mothers
who deliver preterm showed significantly higher protein content than that of
mothers who deliver at term [22, 23]. The mean total protein content in preterm
milk has been reported to range from 3.0 to 1.9 g/dl, and in term milk to vary from
2.2 to 1.1 g/dl over the first 4 weeks postpartum [19, 20, 24–26]. As lactation stage
proceeds from colostrum to transitional milk, a gradual and physiological decrease
in protein quantity occurs in both kinds of milk [26–28]. A decrease of protein levels
by 30% was reported in preterm milk and by 50% in term milk from the first to
eighth weeks of lactation [20, 29]. The concentration of proteins remains relatively
constant thereafter in mature (term) milk. However, according to Lucas and Hud-
son [30], the volume of milk produced is an important determinant of protein
content. They negatively correlated the postnatal age of the donor with milk protein
concentration. Also, for feeding preterm infants, the lower level of total protein and
specific amino acids from donor (typically, term, late lactation) milk alone is limit-
ing, and requires additional supplementation. Many other factors also influence the
protein content of human term milk. Bachour et al. [31] showed that smoking and
mother’s basal metabolic index (BMI) and lactation stage significantly decreased the
protein content (12%) of the term milk. Overweight mothers also showed a lower
milk protein concentrations [32]. The treatment of expressed milk also induces
changes in the valuable nutrients contained in human milk. Ramirez-Santana et al.
[33] evaluated the effect of cooling storage at 4°C and freezing storage at 20°C
and 80°C on bioactive factors in human colostrum. The results interpreted that
colostrum can be stored at 4°C for up to 48 h or at 20°C or 80°C for at least
6 months without losing its immunological properties provided by bioactive pro-
teins. Similar study reported that lactating mother can pump the milk and refriger-
ate it for later consumption without compromising on the antibacterial potency of
their milk against for up to 24 h [34].
Bjorksten et al. [35] and Evans et al. [36] reported no significant changes in
human term milk proteins after freezing for 3 months. Another study suggested
that frozen storage resulted in a lower reduction in various bioactive proteins as
compare to pasteurization in term milk [37] Similarly, Chang et al. [38] revealed a
non-significant decrease in most of the bioactive proteins in frozen as well as in
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low-grade heat treated (below 60°C) term milk. They proposed frozen breast milk
as an alternative choice if fresh breast milk is unavailable. The Academy of
Breastfeeding Medicine has a protocol for home storage of human milk that can be
used to guide mothers in these activities to optimize the integrity of expressed and
stored milk.
3. Breast milk and antimicrobial proteins
Human milk possesses inherent antimicrobial proteins that have been attributed
to the defense against number of pathogens preventing their proliferation and
invasion. The major antimicrobial proteins (AMPr) present in human milk act as
first line of innate defense and are discussed below:
3.1 Lactoferrin
Human lactoferrin (HmLf) a multifunctional whey class of globular glycopro-
tein, found in abundance in human milk. The concentration is highest in colostrum
at 5.5 g/L and decreases between 1.5 and 3.0 g/L in mature milk depending on the
stage of lactation [39]. The decline in lactoferrin concentration is slower in preterm
mother’s milk than in full-term mother’s milk [40]. Lactoferrin is an antiviral,
antibacterial and anti-inflammatory protein. HmLF exert antimicrobial activity
against Gram-positive [41–44] bacteria by either iron-depletion and/or disruption
of bacterial membrane [45]. Lactoferrin also possesses anti-inflammatory properties
and seems to be involved in phagocytic killing and immune responses [46]. The
presence of human lactoferrin in breast fed infants indicate that it survive proteo-
lytic digestion. Higher concentration found in the feces of premature infants
suggests that these proteins play an active role in the infant gut [47].
3.2 Secretory immunoglobulin A (sIgA)
sIgA is the major immunoglobulin belonging to whey group of proteins present
in human milk. The average concentration ranges from 2.0 g/L in colostrum to
approximately 0.5 g/L in mature milk [48]. The secretory component works as a
defense mechanism for the antibody molecules, protecting them from gastric acid
and digestive enzymes, hence, resist digestion [49]. As a result, sIgA molecules
remain active throughout the infants’ gastrointestinal tract and protect against
bacterial infections especially diarrheal diseases which are a major cause of morbid-
ity and mortality in children in developing countries [50]. sIgA bind to pathogenic
bacteria, toxins and other antigenic materials, such as lipopolysaccharide (LPS),
thus, preventing their adherence and penetration into the intestinal epithelium
without triggering inflammatory reactions that could be harmful to the newborn.
This mechanism is called immune exclusion.
Apart from direct binding, sIgA can agglutinate bacteria non-specifically
through oligosaccharide α-side chains of the immunoglobulin molecule. These oli-
gosaccharides bind to fimbrial lectins, e.g., of E. coli and other bacteria [51]. Purified
sIgA from human milk has been shown to protect the breast-fed infant by inhibiting
the adhesion of enteropathogenic Escherichia coli (EPEC) to HEp- 2 cells in cell
culture [52]. Another study demonstrated the ability of human milk sIgA to block
the adhesion of Staphylococcus aureus strain in tissue culture.
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3.3 Lysozyme
This protein constitutes a major fraction of the whey protein of breast milk. It is
present in higher amounts in colostrum (0.36 g/L) and its concentration is slightly
reduced in mature milk to 0.30 g/L [53]. Lysozyme is a protein that can exerts its
antibacterial effect against gram positive bacteria independently by cleaving the 1–4
linkage between N-acetyl glucosamine and N-acetylmuramic acid in their cell wall.
It may also act in concert with lactoferrin to kill both gram-positive and gram-
negative bacteria and perhaps also against viruses. Electron microscopic studies
showed that lactoferrin first binds to LPS in outer membrane of the bacteria creat-
ing holes through which lysozyme can penetrate and degrade the inner peptidogly-
can matrix [8]. It is found intact in the stool of infant showing that it may exert its
activity in the gut of breast fed infant.
3.4 κ-Casein (κ-CN)
k-casein, a small subunit of casein present in breast milk, is a highly
glycosylated (90%) oligosaccharide. Concentration of kappa casein in colostrum is
25 and 1 g/L in mature milk [54]. The antimicrobial properties of the κ-casein
portion of human milk fluids were first reported by Aniansson et al. [55]. κ-casein
was showed to inhibit the adherence of Streptococcus pneumoniae to human respi-
ratory tract epithelial cells in vitro. κ-casein prevents the attachment of bacteria to
the mucosal lining as their oligosaccharides act as a receptor analogue having
structures similar to exposed glycans on mucosal surface [56]. Others have dem-
onstrated an inhibitory effect of κ-CN on the adhesion of Helicobacter pylori to
human gastric mucous cells [57]. These studies clearly established that the actual
anti-infective agent responsible for preventing infection in their respective cell
types was the carbohydrate portion of the glycoprotein. Later, the fucose carbo-
hydrate moiety was specifically identified as the primary factor responsible for
inhibiting adhesion. Studies have also indicated that κ-CN in milk works together
in a synergistic approach with lactoferrin, and sIgA work to protect the new born
against microbial attack.
3.5 Osteopontin (OPN)
It is a multifunctional glycosylated and heavily phosphorylated acidic protein
initially discovered in bones. With high variability among mothers and stages of
lactation, the average concentration of osteopontin in breast milk is approximately
(138  79 mg/L, mean  SD) [58]. Present in low concentration in colostrum but
after 3 days of lactation, high levels are established. The levels decrease with
advancing lactation, but about half maximal levels are maintained beyond 1 year of
lactation [59]. In vitro experiments have indicated that human and bovine milk
OPN are in part resistant to proteolysis in the infant intestinal tract, which makes
OPN a potentially bioactive component of human milk [60]. It also plays an impor-
tant role in immune activation and immune regulation by acting as chemotactic
agent and stimulates both pro- and anti-inflammatory processes. It enhances B
lymphocyte immunoglobulin production and proliferation and also influences cell-
mediated immunity by inducing Th1 cells [61]. Furthermore, it also has been shown
to form complexes with lactoferrin and act as carrier for other immunomodulator
protein to enhance their competencies [62].
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3.6 Haptocorrin
Haptocorrin is a heavily glycosylated protein present at a concentration of 5 mg/
ml in colostrum and 3 mg/ml matured milk. Haptocorrin is a vitamin B12-binding
protein, stable against proteolytic digestive enzymes [46]. As the infants lack
intrinsic factor required for absorption of vitamin B12, hence, haptocorrin may
facilitate vitamin B12 absorption [63]. Even at low concentration, haptocorrin has
been shown to possess antibacterial activity against pathogenic strains of E. coli and
thus may serve as a defense protein against E. coli related infection [64]. However,
more studies delineating the effect of the bacterial strain and it’s mode of action is
required as its antimicrobial role has been shown to be limited to very few
pathogens.
3.7 Lactoperoxidase
A member of whey protein, lactoperoxidase is secreted by mammary glands and
is persistently present during lactation with concentration of 1–1.5 units/ml [65].
Lactoperoxidase is a glycoprotein and it is resistant to proteolysis [66], thus playing
a role in infant host defense. It forms lactoperoxidase system with thiocyanate
(SCN–) present naturally in human milk, and H2O2, which is generated by bacteria
[67]. In the presence of H2O2, lactoperoxidase oxidases SCN– to hypothiocyanite
(OSCN–), which has antimicrobial activity against both Gram positive and Gram
negative bacteria [68]. These chemical reactions also cause leakage of potassium
ions, amino acids, and peptides across the damaged cytoplasmic membrane.
Lactoperoxidase together with sIg and lysozyme help to eradicate microorganisms
from the small intestine without inflammation, contributing to the development of
a healthy microbiome [69].
3.8 α-Lactalbumin
The most well characterized and primary whey protein in human milk is
α-lactalbumin [70, 71], which accounts for 20–25% of total breast milk proteins.
During its digestion, peptides appear to be transiently formed that have
antibacterial and immunostimulatory properties, thereby possibly help in providing
protection against infection. Various hydrolytic products of α-lactalbumin have
shown antimicrobial activity against E. coli, Klebsiella pneumoniae, Staphylococcus,
Streptococcus, and C. albicans [72].
3.9 Mucins
Mucins are high molecular mass glycoproteins (200–2000 kDa) heavily
glyosylated proteins with variable number of tandem repeats, i.e., mucin domains
[73]. Mucins are found within the milk fat globule membranes (MFGM), and
typically make up less than 1% of total protein. At least 16 mucins have been
identified in humans. Mucin-1 and Mucin-4 have been identified as the major
human milk mucins [73]. Mucins provide protection against gastrointestinal and
respiratory tracts infections by decreasing the adhesion of pathogens to the cell
surface. Mucin-1 specifically has been reported to inhibit the invasion of Salmonella
typhimurium, in a model of fetal intestinal cells, at concentrations that are similar to
that of human milk [73]. Sialic acid moiety of mucin-1 interacts with pathogen
thereby inhibiting the ability of the pathogen to bind to its infant host cell surface
glycan receptor.
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3.10 Lactadherin (milk fat globular membrane protein; MFGMP)
Lactadherin is a 46 kDa mucin associated sialyated glycoprotein found in milk
fat globule membrane. In a study reported by Newburg et al. [74], 200 infants in
Mexico City from birth to 2 years of age were closely monitored for rotavirus
infection symptoms. Milk samples were obtained from the respective mothers
weekly until 4 weeks post-partum. The milk samples were taken immediately
before an infant’s episode of rotavirus infection and levels of lactadherin,
butyrophilin, mucin, and secretory IgA were determined. Results indicated that
concentration of lactadherin in the milk samples fed to infants belonging to asymp-
tomatic group was 48.4 (range 5.6–180) μg/mL while in the symptomatic group, it
was lower, i.e., 29.2 (6.2–103.4) μg/mL. No such association between symptom
status and concentrations of butyrophilin, mucin, or secretory IgA was found.
These findings indicated that Lactadherin concentrations showed a significant
association with symptoms in rotavirus-infected breastfed infants and is represen-
tative of a class of non-antibody glycoconjugates in human milk having protective
effect against symptomatic rotavirus infection.
4. Breast milk: reservoir of antimicrobial peptides (AMPs)
Human milk derived bioactive peptides are low-density molecules (5–90 amino
acids) exhibiting their bioactivity features when separated from the parental pro-
teins. These human milk peptides not only act as sources of amino acids, but they
are also involved in immune-modulation, opioid-like activity, antioxidant, antimi-
crobial, and antiviral action, and probiotic action. These peptides when released
may express activity different from that of the parent protein. This may account for
their “encrypted” role other than parent protein after digestion [75]. Nielsen et al.
[76] identified a total of 5264 unique peptides by mass spectrometry deriving from
human and bovine milk proteins. Of these 1722 and 3399 originated from bovine
and human milk proteins, respectively. β-casein accounted for 71.2% of the total
human peptide ion intensity, with αs1-casein and κ-casein combining for an
additional 11.7%.
Anti-microbial peptides (AMPs) exhibit activity against an array of neonatal
pathogens both Gram positive (Staphylococcus aureus, Streptococcus pneumoniae,
Group B Streptococcus, i.e., GBS) and Gram negative bacteria (E. coli, Klebsiella
pneumoniae), mycobacteria, fungi and even the viruses [14, 77–79]. AMPs are
expressed either constitutively or their expression can be inducible in response to
certain pro-inflammatory stimuli. AMPs are cationic peptides that destroy bacteria
in a unique way that is less prone to resistance. They initially target the bacteria via
electrostatic contact at the anionic bacterial surface, i.e., AMPs interact with the
highly negatively charged surface of the membrane consisting of lipopolysaccha-
ride. This is then followed by self-promoted uptake while the AMPs insert and
translocate to the outer bilayer to bind the anionic inner membrane [80]. This leads
to rapid killing and lysis due to serious reduction of membrane integrity at high
concentrations with some AMPs, also having intracellular targets such as DNA [81].
The concept of extracellular entrapment of bacteria by AMPs at epithelial surfaces
and within the bloodstream is also one mechanism.
Although many AMPs of bovine origin have been studies in detail, but we are
focused on detailing the antimicrobial peptides of human origin and their mode of
action. Studying the activity and properties of human origin antimicrobial peptides
will open a new window of alternate therapy targeting the treatment of infections
resilient to the action of antibiotics especially in neonatal scenario. Also, such potent
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peptides can be further isolated, cloned and purified to be incorporated into infant
formula feed acting as a ready therapy given through food to the highly vulnerable
preterm infants. The major antimicrobial peptides present in human milk and their
mechanism of action (Figure 1) reported till date are as follows.
4.1 Defensins
Defensins (2–6 K Da) are small cysteine rich cationic proteins that participate as
host defense peptides against bacteria, fungi and enveloped/non enveloped viruses.
Defensins can be categorized broadly as α-defensins, β-defesins and Ѳ-defensins.
α-defensins are produced in neutrophils and NK cells mostly in a constitutive
manner whereas β-defensins are secreted by epithelial cells of various kinds which
also include mammary gland. Armogida et al. [82] identified expression of hbd-2
gene in 15% of mammary epithelia cells. Baricelli et al. [83] quantified human
β-defensins-2 (HBD-2) levels in colostrum and mature milk from 100 donors. The
colostrum showed concentration ranging from 2.5 to 16.3 μg/ml whereas mature
milk showed a low concentration of an average of 0.97 μg/ml.
They also reported that HBD-2 had potent activity against three opportunistic
pathogens Salmonella, E. coli and Pseudomonas aeruginosa. It also showed activity of
4 μg/ml against multi-drug resistant Acinetobacter baumanii. These molecules have
been shown to form nets to trap bacteria and combat invasion into deeper tissue
[84]. These findings highlight the protective role of this peptide against serious
gastrointestinal infections in neonatal population.
Figure 1.
Summary of different antimicrobial proteins and peptides in human Milk and their action.
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Jia et al. [85] studied the levels of human β-defensins-1 (HBD-1) in human breast
milk by western immunoblotting and reverse HPLC. They detected that level of
HBD-1 was 1–10 μg/ml in mature milk and exhibited antimicrobial activity against
Escherichia coli. In other study, breast tissue sampled from lactating mothers also
showed hBD-1 mRNA expression in mammary gland epithelial cells and in active
milk [86]. HBD1 also showed killing activity against E. coli at a conc. of 5 μg/ml and
against Salmonella enteritidis through formation of entrapping nets in a redox
dependent mode of action [87]. HBD-1 may act synergistically with other peptides
present in breast milk. Also, HBD-1 acts as a chemotactic agent to recruit dendritic
cells, T-cells to mucosal surfaces (respiratory, gastrointestinal, and nasopharynx)
thus acting as a link between innate and adaptive immunity for the neonate [88].
4.2 Cathelicidins
Cathelicidins are multifunctional bactericidal peptides characterized by a highly
conserved N-terminal domain of about 100 amino acid residues. This 14 kDa cathelin-
like domain is flanked by a signal peptide domain (approximately 30 residues long)
on its N-terminus, and by an antimicrobial peptide region on its C-terminus. The
single 16 kDa human cathelicidin is denoted as hCAP18 and it becomes active only
upon proteolytic cleavage into cathelin domain and cathelicidin-derived AMP yield-
ing LL-37 [89]. This LL-37 is the only human cathelicidin-derived AMP secreted by
mammary gland and present in human milk [90].
Human cathelicidin hCAP18/LL-37 mRNA expression was confirmed in human
milk cells showing an increase in expression levels at 30 and 60 days after parturi-
tion. Further, western blot analysis showed that LL-37 was secreted and present in
the mature peptide form in human milk and is present in expressed breast milk
(EBM) of mothers of both term and preterm infants [91].
LL-37 exhibits antimicrobial activity against both Gram-positive and Gram-
negative bacteria., The ability of cathelicidins and defensins to directly confer
protection against bacterial colonization of epithelial surfaces has been shown in
gut, lung, and skin [92, 93]. Chen et al. [94] also showed synergistic effect of
antibacterial agents’ human beta-defensins, cathelicidin LL-37 and lysozyme against
Staphylococcus aureus and Escherichia coli. Scheid et al. [95] examined antimicrobial
activity of LL-37 (15 μg/ml) in hirudin-anticoagulated preterm and term human
cord blood against Staphylococcus aureus, Staphylococcus epidermis and Candida
albicans by CFU assay. LL-37 enhanced the antibacterial/antifungal activity against
all three pathogens in term blood and against S. epidermidis in preterm blood.
4.3 Lactoferricin
Although Lactoferrin is not readily digested and is found intact in stool sample
of infants, it is digested partially to give a peptide called “Lactoferricin”. This
peptide is able to inhibit adherence of Escherichia coli to intestinal cells [96].
Lactoferricin is also active against clinical isolates of enterohemorrhagic E. coli
0157H:7 at concentrations significantly less than either the lactoferrin hydrolysate
or lactoferrin, itself [97]. The mechanism involved in killing the target bacteria is
through membrane perturbation and this peptide also acts synergistically with other
proteins and antimicrobial agents [98]. In addition to Lactoferricin, the role of Lf
(1–11) has also emerged in the recent past [99] as Lf(1–11) was demonstrated to be
active against gram-positive bacteria (Staphylococcus spp. and Streptococcus mitis)
as well as gram-negative bacteria (Acinetobacter baumannii, Pseudomonas spp.,
Klebsiella spp., and E. coli) [98, 100].
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4.4 Novel endogenous antimicrobial peptides
• β-casein 197: Fu et al. [101] used tandem mass spectrometry (MS/MS) to
identify the peptides in both term and preterm human milk, and identified a
peptide derived from β-casein: a sequence (197–213) from human β-casein. It is
a 17 amino acid (197–213) peptide fraction of β-casein that is a newly found
endogenous peptide hydrolyzed human from β-casein. It exhibits potent
bactericidal property against E. coli, S. aureus, Yersinia spp. but no activity was
seen against Bacillus subtilis and Klebsiella pneumoniae by disk diffusion assay.
Electron microscopy images of treated cells revealed leaky cytoplasm and bleb
like structures indicating the β-casein 197 peptide killed cells by means of
membrane permeabilization instead of DNA binding.
• PDC213: Sun et al. [102] reported another novel endogenous peptide from
human milk called PDC213. PDC213 was derived from β-casein (213–266
amino acid residue). This endogenous peptide identified by the group
exhibited potent antimicrobial activity against S. aureus and Yersinia
enterocolitica using in vitro assays. Furthermore, the group also found that
PDC213 can effectively permeabilize the bacterial membrane to cause direct
damage to the bacteria.
5. Neonatal infections: a brief overview
The first 28 days of life, i.e., the neonatal period is the most crucial and the most
vulnerable time for survival of newborn. It is reported that in 2018, 2.5 million
children died in the first month of their life which means 7000 neonates die each
day with one-third dying on the day of birth [103]. An estimated 16 million neona-
tal deaths occur annually due to infection representing 40% of all neonatal deaths
which is a very high percentage. Among the infections, diarrhea, pneumonia, neo-
natal sepsis and malaria are the leading causes [104]. Despite recent advances in
neonatal intensive care and current treatment interventions, the global burden of
neonatal deaths due to infections is high and represents a challenge especially in
developing and poorer countries. The leading neonatal infections that account for
the greatest morbidity and mortality among neonatal population have been
highlighted below and in Table 1.
5.1 Neonatal sepsis
Neonatal sepsis remains serious complication especially in preterm and VLBW
infants. Globally the greatest burden of neonatal sepsis falls in low resource devel-
oping countries [105]. It is divided as early onset sepsis (EOS) that occurs in first
week of life and late onset sepsis (LOS) occurring after 1 week acquired after birth.
Group B streptococcus (GBS) remains the dominant cause of EOS with 20–33%
mortality in premature infants [106, 107]. E. coli is the second most common cause
isolated from such cases especially in VLBW infants [108, 109]. LOS is largely
caused by organisms acquired in postnatal period in infants exposed to invasive
procedures, tubings, devices etc. Coagulase negative Staphylococci (CoNS) has
emerged as one of the most commonly isolated pathogen in VLBW infants
(22–65%) of LOS infection [110, 111]. S. aureus is associated with 4–8% of such
cases of LOS. The increased incidence of MRSA isolates from neonatal sepsis is a
matter of concern as 25% of infants infected with MRSA die [112].
10
Infant Feeding - Breast versus Formula
Among Gram negative organisms, E. coli (20–31% of LOS cases), Klebsiella
pneumoniae, Pseudomonas spp. are also isolated with worse outcomes and high
mortality seen.
5.2 Necrotizing Enterocolitis (NEC)
NEC is a common gastrointestinal emergency among preterm and very low birth
weight (VLBW) infants but rare in full term infants. Its exact pathology and mech-
anism still has to be clearly understood. Despite advanced care of preterm infants in
Neonatal Intensive Care Units (NICU), NEC remains the leading cause of morbidity
and mortality in this population. It is estimated that 1–5% of all NICU admissions
and 5–10% of all VLBW (≤1500 g) are affected or at risk of developing NEC with
about 30% of them unable to survive their first week itself [113].
In 80% cases of NEC with intestinal perforation, members of Enterobactericeae
especially E. coli, Klebsiella pneumoniae were present in peritoneal fluid in 75% of
cases, Coagulase negative Staphylococci (CoNS) in 14% of cases and anaerobes in
6%. Even cases of MRSA associated with few cases of NEC have emerged [114].
5.3 Neonatal pneumonia
It is estimated that pneumonia contributes to more than 1.2 million neonatal
deaths and an unknown number of still births each year worldwide. Early onset
pneumonia is acquired during labor/delivery and late onset pneumonia is acquired
during postnatal period from colonization of endotracheal tubing, ventilator tubing,
Neonatal infections Etiological agents (Bacterial) involved
Early onset sepsis (EOS) Dominant: Group B Stretococcus (GBS), E. coli
Less common: Str. pyogenes, Str. pneumoniae,
Haemophilus influenzae
Late onset sepsis (LOS) Commonly isolated: Coagulase negative Staphylococci
(CoNS), S. aureus
Others: Acinetobacter baumannii, Str. pneumoniae
Early onset pneumonia (EOP) Str. pneumoniae (25% of cases), Group B Streptococcus
(GBS), E. coli, Klebsiella spp., S. aureus
Late onset pneumonia (LOP) S. aureus (dominant cause), Str. pyogenes, Str.
pneumoniae, E. coli (less common)
VAP Methicillin sensitive S. aureus (MSSA) and Methicillin
resistant S. aureus (MRSA), CoNS, Streptococcus
pneumoniae
Necrotizing Enterocolitis (NEC) Members of Enterobactericea (E. coli, Uropathgenic
E. coli (UPEC), Klebsiella pneumoniae)
Pseudomonas aeruginosa, Coagulase negative
Staphlycocci (CoNS), MRSA, Clostridium difficle
Infantile diarrhea ETEC, EPEC, Shigella flexneri, Salmonella spp.
Neonatal skin infections S. aureus, S. epidermidis, CoNS, Strep. pyogenes, Strep.
pneumoniae
Other infections (Otitis media, sinusitis,
conjunctivitis, urinary tract infections)
S. aureus, S. epidermidis, Str. pyogenes Str. pneumoniae,
Group B Streptococci (GBS)
Pseudmonas aeruginosa, E. coli, Klebsiella spp.
Table 1.
Commonly encountered neonatal infections in preterm and term neonates along with their etiology.
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intravenous lines, from clinical staff and hospital staff after 48 hours or more of
invasive mechanical ventilation [115]. The causative agents involved have been
delineated in Table 1. Streptococcus pneumoniae and Group B streptococcus (GBS)
are commonly encountered in early onset cases. Ventilator associated pneumonia
(VAP) is on common rise as it has emerged as the second most reason for antibiotic
intervention in NICU [116, 117] with S. aureus being the dominate cause due to its
biofilm forming ability. Rising rates of resistance to common antibiotic means more
fatality rates from neonatal pneumonia especially in poorer nations emphasizing on
need to exploit alternative intervention strategies.
5.4 Infantile diarrhea
Diarrhea has been described as the leading cause of deaths due to infection in the
neonatal period. It accounts for more than 10.5% of all deaths and despite efforts
focused to reduce the related mortality, it still represents the main preventable
cause of deaths in newborns and young children [118, 119]. The underlying cause
may be due to bacterial, viral and parasitic origin. Enterotoxigenic E. coli (ETEC),
Enteropathogenic E. coli (EPEC), Shigella flexneri, Salmonella spp. are all involved in
different cases of bacterial diarrhea outbreaks more concentrated in slum areas.
In addition to this, other neonatal infections commonly encountered include
conjunctivitis, skin infections (Bullous impetigo, skin abscess, scalded skin
syndrome), Otitis media, urinary tract infections, etc.
6. Protective role of breast milk against neonatal infections
Early and exclusive breastfeeding is one of the most important intervention
strategies to reduce the risk of developing serious bacterial infections and related
infant mortality [119, 120]. The risk of non-viral diarrhea is higher for non-breast-
fed infants in the first 4–6 months of their life. A recent meta-analysis suggested
that infants who were breast-fed for >4 months showed a three times reduced
frequency of developing severe respiratory tract infection as compared with infants
who were not breast-fed [121]. In other studies, breast milk in protection against
otitis media and urinary tract infections was reported [122, 123]. There is also an
increased risk of mortality in children due to suboptimal or insufficient
breastfeeding, which is responsible for 11.6% of total deaths of children under
5 years old [124]. Mother milk is also the best option for preterm and very low birth
infants as studies indicate the over expression and increased level of range of
functional peptides in preterm milk that may act as ready source of protection for
the vulnerable infant. Preterm infants due to their low intake of breast milk vol-
umes and associated proteins and peptides may be actually at higher risk of devel-
oping serious life threatening infections like NEC, late onset sepsis, pneumonia, etc.
[75]. Table 2 summarizes the finding of few of the important studies elucidating the
protective role of breast milk against common neonatal infections.
The antimicrobial proteins and range of antimicrobial peptides present in breast
milk act synergistically adopting multiple mechanisms to inhibit disease progression
by the invading pathogen. Human milk proteins and their derived peptides have
been discussed in Sections 3 and 4. Antimicrobial peptides released from any source
including breast milk circulate in infants’ blood stream and provide an ongoing
source of low-level of non-specific immune defense against potential invasive
pathogens. LL-37 along with bactericidal permeability increasing protein (BPI) has
been shown to be present in higher levels in infant’s blood suffering from acute
blood stream infections. Also, LL-37 exhibits significant inhibitory activity against
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Target infection Reference Objective and study design Result Final outcome
Neonatal sepsis [125] Objective: To investigate the protective efficacy of
breastfeeding against neonatal sepsis high risk population
in Lahore, Pakistan.
Study Design: A case–control study where 42 cases of
neonatal sepsis from hospital and 270 age matched controls
acted as participants Exclusive breast feeding was as most
babies were partially breast fed and a few given formula
feed or animal milk.
In the partially breast fed group there were
19 cases and 253 controls while in the group
given no breast milk there were 23 cases
and 17 controls. Therefore, the incidence of
breast feeding was less among the cases
than the controls, with an odds ratio of 18.
Even partial breast feeding protects against
neonatal sepsis in premature infants.
Neonatal pneumonia [126] Objective: To assess whether breast feeding protects young
children against pneumonia and whether this protection
varies with age.
Study Design: A nested case control study in Brazil where
152 infants aged 28–364 days who had been admitted to
hospital for pneumonia participated in the study.
Results indicated that the babies who were
not being breast fed were 17 times more
likely to be admitted with pneumonia as
compared to breast fed infants and this risk
was higher in the initial 3 months of
infancy.
Breast feeding protects young children






[127] Objective: To assess the potential role of exclusive
breastfeeding in reducing the incidence of deaths due to
acute respiratory infections (ARI) and diarrhea
Study Design: A prospective observational study was
conducted on a birth cohort of 1677 infants who were born
in slum areas of Dhaka, Bangladesh and followed from
birth to 12 months of age. On basis of verbal autopsy and a
structured questionnaire, the mortality attributable to ARI
and diarrhea was measured.
The overall risk of infant deaths from all
causes was 2.23 fold higher in infants with
no or poor breast feeding as compared with
infants with exclusive breastfeeding while
the risk of deaths due to ARI and diarrhea
was still higher, i.e., 2.40- and 3.94-fold
higher in no or partially breast fed babies.
Exclusive breastfeeding in the first few
months of life significantly decreases onset
of ARI and Diarrhea.
Lower respiratory
tract illness
[128] Objective: To examine breastfeeding and the risk of
hospitalization for lower respiratory tract disease in healthy
full-term infants with access to modern medical care.
Study: It was a meta-analysis of 33 studies.
Result from this meta-analysis indicated
that among the infants with severe
respiratory tract illnesses resulting in
hospitalizations, more than tripling of them
were those who were not breastfed for the
initial 4 months of their infancy.
Breast feeding decreases risk of lower
respiratory illnesses.
NEC [129] Objective: To determine the association between human
milk (HM) intake and risk of necrotizing enterocolitis
(NEC) or death among infants (401–1000 g birth weight).
Results indicated 13.6% infants died and
developed NEC after 14 days of their birth.
However, after the initial 14 days, the
Dose dependent effect was evident
between intake of human milk and























































Target infection Reference Objective and study design Result Final outcome
Study Design: Analysis of 1272 infants in the National
Institute of Child Health and Human Development
Neonatal Network Glutamine Trial was performed to
determine if increasing HM intake was associated with
decreased risk of NEC or death.
incidence of NEC decreased by a factor of
0.83 with every 10% increase in the total
intake of Human milk. Therefore, a strong
dose association was seen with a decreased
risk of NEC or death among infants who
received 100% human milk as a proportion
to total enteral intake.




[130] Objective: To explore the use of mothers’ own milk
(colostrums, transitional milk, and mature milk) as oral
care in the ventilator-associated pneumonia (VAP)-
prevention bundle of mechanically ventilated preterm
infants weighing 1500 g or less.
Study Design: Retrospective descriptive involving
mechanically ventilated preterm infants weighing 1500 g or
less admitted to a regional level III NICU in the Gulf South.
To these, oral care with mothers’ own milk was
implemented as part of the VAP-prevention bundle and the
outcomes that were assessed included rate of positive
tracheal aspirates, positive blood cultures, the number of
ventilator days, and length of stay.
Rates of positive tracheal aspirates and
positive blood cultures showed reduced
values in infants receiving oral care with
mothers’ own milk.
Use of mother’s milk as part of oral care as
VAP-prevention bundle is a feasible safe




[131] Objective: To investigate the effect of human breast milk
(colostrums) in preventing neonatal conjunctivitis.
Study Design: Randomized clinical trial where the
intervention group with culture-negative eye swab
received two drops of colostrum in each eye, antibiotic
group received erythromycin ointment (0.5%), while
control group received no treatment. All neonates were
followed for the occurrence of clinical conjunctivitis for
28 days.
Results indicated that application of
colostrum significantly decreases the onset
of neonatal conjunctivitis in the test group
as compared to control group (p = 0.036).
A positive effect with application of
Human colostrums was found and thus can
act as a favorable option in place of
antibiotics against neonatal conjunctivitis.
NEC [132] Objective: To study the effects of feeding exclusively
human milk (EHM) diet to premature infants on reducing
the incidence of necrotizing enterocolitis (NEC) associated
In the control cohort, NEC onset after day 7
of life occurred in 15 of 443 infants (3.4%),
significantly more than in the EHM cohort
Changing to an EHM milk diet through
33 weeks PMA reduced the incidence of


















Target infection Reference Objective and study design Result Final outcome
with enteral feeding.
Study Design: An observational study included all
premature infants admitted to Level III NICU, at less than
33 weeks gestational age. An EHM diet was recommended
which eliminated all bovine-based artificial milk, including
bovine-based fortifier through the study period.
where NEC occurred in two of 199 infants
(1%) (p = 0.009).
NEC, LOS [133] Objective: To examine the effect of human milk on
morbidity, specifically necrotizing enterocolitis (NEC), late
onset sepsis (LOS), retinopathy of prematurity (ROP),
bronchopulmonary dysplasia (BPD) and
neurodevelopment in infants born ≤28 weeks’ gestation.
Study Design: Systematic review and meta-analysis where
online databases were searched, and comparisons were
grouped as follows: exclusive human milk (EHM) versus
exclusive preterm formula (EPTF), any human milk (HM)
versus EPTF, higher versus lower dose HM.
Human milk intake was associated with a
clear protective effect against NEC, with a
4% reduction in incidence. Intake of
exclusive human milk (EHM) in any
volume was superior to intake of EPTF and
the higher the dose the greater the
protection.
Improving the intake of mother’s own milk
(MOM) and/or donor HM results in
reducing the morbidity in this population.
Table 2.























































growth of S. aureus and S. epidermidis, two of the common pathogens involve in
neonatal skin infections as well as cases of late-onset sepsis [134]. HBD-2 is the
predominate defensin actively participating in reducing the incidence of respiratory
infections and since preterm infants have lower levels of lung AMPs, they are
unable to clear pathogens effectively [135]. Similarly, higher concentrations of
HBD-2 appears to have a protective role once NEC pathology is established and in
severe NEC. Low HBD-2 expression is a predisposing factor for developing NEC in
preterm and low birth weight infants [136]. Low levels of defensins (HBD-1 and
HBD-2) in preterm infants are associated with increased incidence of intestinal
pathology and onset of NEC. Animal models have showed that depletion of Paneth
cells rich in defensins followed by enteric infection in test animal resulted in a
clinical picture akin to human NEC [137]. HBD-2 is directly involved in killing
range of nosocomial pathogens (E. coli, S. aureus, Klebsiella, Salmonella) as showed
by in vitro assays [138, 139].
Lactoferrin (LF) is a major contributor showing direct bactericidal action on
range of neonatal pathogens. Murakami et al. [91] showed that 32 μM concentration
of Lactoferrin was able to exhibit potent killing of 77% Group A Streptococcus
(GAS), 40% S. aureus and 17% E. coli. Therefore, LF supplementation in VLBW
infants is an ideal prophylactic treatment option for reducing the incidence of
deaths and complication due to serious infections such as blood stream infections,
infantile diarrhea, NEC in this population. These findings form the rationale for
further exploiting the potential clinical utility of antimicrobial proteins and peptides
in the prevention and treatment of infections in infants.
7. Preterm infants: a special case
Prematurity has been reported to be second most common cause of death in
children under 5 years of age. Preterm infants are those born before 37 weeks of
completed gestation, extremely preterm are those born at less than 28 weeks of
completed gestation whereas very preterm refers to infants born between 28 and
32 weeks of gestation [140]. The incidence of premature birth and related deaths
have been steadily increasing each year with an estimated 15 million babies born
preterm [15]. Such infants are at increased risk of development of serious life
threatening infections such as necrotizing enterocolitis (NEC), late onset sepsis
(LOS), bloodstream infections, pneumonia and other complications.
Therefore, the challenge is to further improve the future of preterm infants with
early protection to be given immediately after birth starting in the neonatal care
units.
Maternal milk, a complex fluid with several bioactive proteins and peptides is
beyond doubt the best option for the preterm infant [141]. Literature reveals that
bioactive factors are found in much higher levels in preterm milk as compared to
full-term milk and such factors are totally lacking in formula milk and significantly
decreased in donated milk. This focuses on the use of human milk fortifiers
containing the useful functional peptides as an ideal choice acting as a prophylactic
supplement to protect the preterm infant where breastfeeding is unavailable or
insufficient.
Preterm milk has higher protein and peptide levels as reported by past workers
[75, 142]. Ferranti et al. [143] found more than 100 peptides originating by break-
down of casein protein from mother who gave birth at 25 week gestation which is a
case of extreme preterm delivery. Similarly, Armaforte et al. [144] also found via
2D-SDS page technique that low molecular weight casein fragments are over
expressed in preterm milk as compared to term milk whereas intact αS1-casein and
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ß-casein were present in low concentrations in preterm milk than term milk. Simi-
larly, Dallas and co-workers [145] reported that protein breakdown was higher with
higher level of plasmin activity seen in preterm milk. This indicates higher protein
degradation and higher release of endogenous and antimicrobial peptides in pre-
term milk. These findings clearly indicate that antimicrobial peptides present in
higher amounts act as a ready source to fight off infection at different levels for the
wellbeing and early life protection of the preterm infants while the infants own
protein digestion ability is not fully developed while compensating for the under-
developed innate system of these vulnerable preterm infants.
Ronayne et al. [146] studied the level of lactoferrin in term and preterm milk
and observed that the levels of lactoferrin remained constant in preterm group from
eight post-partum day onwards while the levels showed a significant decline in term
milk. This indicates that high levels are very much required in maintaining protec-
tive barrier against pathogens in preterm infants. Albenzio et al. [147] also found
while studying lactoferrin levels from 28 mothers belonging to term and preterm
cases that highest values of lactoferrin were detected in preterm infant maternal
milk from infants with low weight (less than 1400 g). These findings again point
towards use of tailored supplementation strategies of Lactoferrin in neonatal units
and even after home discharge. The newly isolated endogenous peptides mentioned
earlier in Section 4.4, i.e., PDC213 and ß-casein-197 have also been reported to be
present in significantly higher concentrations in preterm milk as compared to term
milk samples suggesting the role of breast milk naturally tailored to aid in giving
maximum protection to such infants.
Human milk peptides also play an important role in preventing the onset of
serious infections in VLBW infants. Meinzen-Derr et al. [129] studied the associa-
tion between total human milk intake and the risk of developing necrotizing
enterocolitis (NEC), a common cause of early death in extremely low birth infants.
After, analysis of 1272 infants in a multicenter randomized, double-blind trial,
results demonstrated protective effect of human milk intake with a dose dependent
relationship seen between milk intake volumes and risk of developing NEC or death
in such low birth weight infants. Similar cohort study also reported significantly
lower rates of sepsis and death in low birth infants receiving less than 50 ml per kg
per day of fortified human milk [148]. Sisk et al. [149] also reported six-fold
decrease in the odds of NEC among 202 very low birth infants that received at least
50% human milk intake. Trend et al. [150] recently investigated the levels and
antimicrobial activity of antimicrobial proteins and peptides in breast milk con-
sumed by preterm infants, and whether deficiencies of these factors were associated
with late-onset neonatal sepsis (LOS). They collected breast milk from mothers of
preterm infants (32 weeks gestation) was collected on days 7 (n = 88) and 21
(n = 77) postpartum and concentrations of lactoferrin, LL-37, HBD-1 and HBD-2
were measured. Results indicated that levels of most AMPs and antibacterial activ-
ity in preterm breast milk were higher at day 7 than at day 21. The consumption of
AMPs was significantly lower in preterm infants who subsequently developed LOS
compared to matched controls. This highlights the need for research to improve
upon the total feed intake, i.e., feeding tolerance, feeding volumes or increasing the
total quantity of milk AMPs consumed through supplementation, that may be
useful in reducing the risk of LOS in preterm infants.
7.1 Human milk fortification for preterm protection
Human milk is beyond doubt the best option to be given to the preterm. Human
breast milk has many important proteins and peptides totally absent or present in
low levels in bovine milk. For example, lysozyme is 1000 times highly concentrated
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in human milk than cow’s milk. Osteopontin which is essential in establishing
immunity is 10 times more concentrated in human milk. Similarly, Lactoferrin is 20
times more concentrated in human milk and is an excellent antimicrobial agent
along with bifidogenic properties [151]. As per WHO and American Academy of
Pediatrics, pasteurized Human Donor Milk (HDM) is recommended as a second
choice where mother’s own milk is unavailable to the preterm infant [152]. How-
ever, pasteurization may reduce some of the important immune cells, bioactive
proteins and functional peptides therefore research is now being focused on to
fortify human milk to fulfill the need of the preterm infant. A randomized clinical
trial reported that oral lactoferrin supplementation to preterm infants showed a
decreased incidence of late-onset sepsis, a common cause of early deaths in such
infants [153]. Enrichment of donated milk with essential disease fighting proteins
and peptides to be given as soon as possible and until discharge from hospital is
required for the preterm infant as recommended by European Society of Pediatric
Gastroenterology, Hepatology and Nutrition [154]. Clinical study on bovine
lactoferricin added to infant formula showed significant reduction in upper
respiratory diseases in such infants aged 6–12 months of age [155].
Manzoni et al. [156] also reported a reduction in sepsis cases in premature
infants which were given oral supplements of bovine lactoferricin. This opens a new
window of use of supplementation of human lactoferrin based fortifiers acting as a
therapy for the target infants.
Low birth weight infants may take very low volumes of mother’s milk and due to
these low volume intake, the levels of useful bioactive peptides may also be defi-
cient in such infants. In such cases, human milk should be supplemented with
external factors so that even low volumes carry enough of the protective peptides to
meet the demand of the preterm and VLBW infants.
European milk Bank Association working group recognizes standard fortifica-
tion as the most utilized regimen in NICU. It also encourages the concept of “Indi-
vidualized Fortification” to optimize nutrient uptake further introducing the
concept of “Adjustable Fortification” and “Target Fortification” to specifically
modify the human milk to be administered to such infants [157]. However, we need
to know more about the complexity of the various components of breast milk as
there is a lot of variability in the levels and activity of different proteins and
peptides from one mother to other and from one infant to other.
8. Breast milk in era of antibiotic resistance
Antimicrobial resistance is one of the leading global threat to public health
worldwide. The VLBW and preterm infants admitted to NICU are at an increased
risk of developing range of nosocomial infections and if such an infection is caused
by a resistant strain, the situation becomes still worse to treat. Neonates are partic-
ularly at risk of exposure to resistant strains within the hospital environment that
includes methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant
S. aureus (VRSA), methicillin resistant Staphylococcus epidermidis, penicillin
resistant strains of Streptococcus pneumoniae, extended spectrum beta-lactamase
producing E. coli, Klebsiella pneumoniae, etc. [158–160].
Mortality is higher for children with drug-resistant infections, such as MRSA (a
common skin and soft tissue infection) and infections caused by extended spectrum
beta-lactamase-producing bacteria [161]. It is estimated that sepsis infections due to
resistant strains accounts for approximately 214,000 neonatal deaths each year
[162]. There is an urgent need for development of novel antibacterial drugs with
unique mechanism of action that are not susceptible to existing resistance mecha-
nisms being adopted by the bugs.
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Human milk proteins and peptides offer a potent solution to fight life threaten-
ing infections especially in the infant population. It has been postulated by many
workers that bacterial resistance to antimicrobial proteins and peptides is much less
likely to evolve than the conventional antibiotics owing to their broad non-specific
antibacterial mechanism of action that include membrane disruption and inhibition
of cellular proteases [163, 164]. Also, most of these proteins and peptides work in a
Study Milk peptide involved Major findings
[166] Ranalexin Ranalexin (belonging to cathelicidin class) along with lysostaphin
combination found to rapidly kill MRSA strain without affecting
skin normal flora.
[167] Indolicidin and Ranalexin A group designed four hybrid peptides (Indolicidin and
Ranalexin) that exhibited strong antibacterial activity against
MRSA in vitro.
[168] Indolicidin Indolicidin—another family of peptides belonging to cathelicidin
alone as well in combination with antibiotic was able to clear
MRSA biofilm.
[169] LL-13 and LL-17
(truncated forms of
LL-37)
LL-37 and its truncated forms (LL-13 and LL-17) alone or in
combination with vancomycin showed that both the truncated
forms showed significant synergy and increased the susceptibility
of VRSA to vancomycin. These two peptides also showed a strong
ability to inhibit in vitro MRSA biofilm formation.
[170] LL-37 An in vitro and in vivo study of Nafcillin (b-lactam drug)
identified that it enhances killing of MRSA by increasing the
binding of LL-37 to the MRSA membrane.
[171] LL-37 and IDR-1 LL-37 and IDR-1 (innate defense regulator peptide) useful in
ameliorating MRSA induced pneumonia using in vivo model of
pneumonia in C57Bl/6 mice. The peptide combination was able to
restore pulmonary function and decrease release of inflammatory
cytokines in vivo through their immunomodulatory effect.
[172] Recombinant hCAP18/
LL-37
Reported prokaryotic expression of full length hCAP18/LL-37 and
its cathelin like prosequence. The workers showed that human
cathelin like domain acts as a cysteine proteinase inhibitor and
showed potent in vitro activity against resistant strains of E. coli
and MRSA.
[173] Human lactoferrin Study reported that the bacteriostatic activity of human
lactoferrin is solely due to its iron-chelating binding properties and
is not influenced by antibiotic resistance of the pathogen involved.
Therefore, therapeutic approach based on the use lactoferrin




Reported a novel antimicrobial peptide structurally derived from
human milk protein lactoferrin, HLR1r.
They demonstrated potent activity against MRSA using in vivo
model of pig infected with MRSA. The peptide also exhibited anti-
inflammatory properties with significant reduction in
inflammatory cytokines (TNF-α, IL-6 etc.)
[175] Recombinant Lactoferrin
(rLF)
Studied the efficacy of novel recombinant mouse lactoferrin to
protect MRSA infection in a mouse model of peritonitis. The
protein exhibited unique immunomodulatory mechanism in
ameliorating the infection by decreasing the levels of
inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-10) post
lactoferrin treatment.
Table 3.
Summary of role of milk derived bioactive peptides activity against drug-resistant bacterial pathogens.
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synergistic manner and thus work more efficiently in combination therapy. This
also further decreases the frequency of developing of resistant mutants within the
target population. Recent study at University of Helsinki examined 16 mother-
infant pairs for antibiotic resistance patterns in the infant gut. The result showed
that infants that are breastfed for at least 6 months have less antibiotic resistant
bacteria in their gut as compared with babies fed for a shorter time [165]. The major
studies focused on the evaluation of human milk derived proteins and/or peptides
and their activity against resistant bacterial strains either in their purified form or in
recombinant form are summarized in Table 3.
There is an urgent need for developing novel antibacterial drug with unique
mechanisms of action that are not susceptible to existing resistant mechanisms.
One such breakthrough discovery has been the purification of protein-lipid com-
plex from human milk. Marks et al. [176] reported for the first time, the role of
HAMLET, a novel protein-lipid complex purified from casein fraction of human
milk. HAMLET stands for Human α-lactalbumin made lethal to tumor cells. This
complex was able to kill both the resistant and sensitive strains of Streptococcus
pneumoniae, leading cause of neonatal pneumonia and deaths [177]. Also, HAMLET
complex when used along with common antibiotics (Penicillin, erythromycin,
gentamycin) actually potentiated their effect as pneumococci was made more sus-
ceptible as demonstrated in vitro biofilm model and in vivo mice nasopharygeal
colonization model. The complex also showed activity against resistant strains of
Haemophilus influenzae andMoraxella spp. The protein complex binds to bacteria
and stops the flow of ions in and out of the cells, it also blocks important enzymes
required by the bacteria to obtain energy. This unique mechanism makes the bac-
terial cell weak and easily susceptible to damage by common antibiotics as HAM-
LET synergy reduced the dose of antibiotics by a factor of eight to kill MRSA, VRSA
and S. pneumoniae. It was able to re-sensitize MRSA to methicillin and vancomycin
intermediate S. aureus (VISA) to vancomycin by depolarization of bacterial mem-
brane thus dissipating the Proton motive force leading to more access and easy
binding of drug to target bacterial cell [178, 179].
9. Utility of human milk derived antimicrobial peptides and future
implications
The potential role of various antimicrobial proteins and peptides present in
breast milk against the large array of neonatal infections warrants serious future
work towards decreasing neonatal morbidity and deaths by further exploiting their
clinical utility.
Cellceutix Corporation has completed phase II trials of Brilacidin (synthetic
analog of human defensin) in treating acute bacterial skin infections and preclinical
testing against otitis media and ocular infections [78]. Lytix Biopharma has com-
pleted phase II trials of synthetic peptide, i.e., LTX-109 in impetigo (a problematic
condition primarily affecting young children). Talactoferrin, a recombinant human
LF, has been tested in a phase I study in preterm neonates [180]. Other AMPs, such
as LF 1-11 (hLF1-11), have undergone safety and tolerability testing for delivery in
healthy volunteers [181]. The use of recombinant congeners of AMPs represents an
ideal treatment to improve circulating levels and thus improve outcomes from
bacterial infection in infants especially in preterm infants. These peptides either
induced endogenously or as exogenously administered congeners, may help prevent
and treat infections in highly susceptible infants in early life. This is possible
through production of recombinant human milk proteins in large quantities to be
used for the manufacture of fortified infant formula for special cases. Ward et al.
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[182] reported the production of commercial quantities of bioactive recombinant
human lactoferrin in Aspergillus awamori. The technology combined with strain
improvement program yielded high concentration of intact recombinant
lactoferrin. Also, the use of transgenic animals as bioreactors for the synthesis of the
recombinant proteins secreted into milk is worth exploring [183, 184]. With the
advent of targeted genome editing technologies like CRISPR/Cas9 system, it has
been possible to generate economically important animals that produce recombi-
nant proteins in milk. Therefore, future strategies need to focus on isolation of
unidentified novel milk peptides and their recombinant congeners for mass pro-
duction that can be administered as supplementary feeds for prevention and treat-
ment of the most devastating neonatal infections such as pneumonia, neonatal
sepsis, diarrheal diseases, NEC, etc.
10. Conclusion
Human breast milk is the most powerful functional food known. It is a reservoir
of bioactive proteins and peptides that contribute to the enormous health benefits
of breast milk. Antimicrobial proteins and peptides present in breast milk confer
protection against microbial insult. They play an active role against invasion by
neonatal pathogens through direct and indirect mechanisms thus decreasing the
associated neonatal morbidity and mortality. Further, these peptides are expressed
at higher levels in preterm milk than term milk acting as ready source of protection
for the preterm and VLBW infants. In the era of antibiotic resistance, the need to
exploit these unique milk derived peptides become still more important as they
represent an important alternative strategy to fight against drug resistant infections
that is on the rise in the neonatal population as well. Research focusing on incorpo-
ration of novel antimicrobial proteins and peptides in formula feed or to be given
along with donor milk may allow for providing early life protection to the preterm
infants decreasing the incidence of premature deaths due to serious life threatening
neonatal infections. The role of recombinant DNA technology for mass production
of these novel antimicrobial peptides followed by their safety and efficacy trials
warrants future work.
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